See­los Ther­a­peu­tics 'tem­porar­i­ly' stops study in rare neu­ro dis­or­der for busi­ness rea­sons

Mi­cro­cap biotech See­los Ther­a­peu­tics is halt­ing en­roll­ment of its study in spin­ocere­bel­lar atax­ia type 3 (al­so known as Macha­do-Joseph dis­ease) be­cause of “fi­nan­cial con­sid­er­a­tions,” and in or­der to fo­cus on oth­er stud­ies, the com­pa­ny said to­day, adding that the pause would be tem­po­rary.

The study will con­tin­ue with the pa­tients who have al­ready en­rolled, and the da­ta from them will be used to de­cide whether to con­tin­ue en­rolling oth­ers in the fu­ture.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters